IP Library Granted Patent US 6,914,069
Granted Patent B2
US 6,914,069 · App. 09/860,658 · Granted Jul 5, 2005

Pharmaceutically active compounds and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,914,069
App. No.
09/860,658
Granted
Jul 5, 2005
Kind
B2
Abstract

The invention provides substituted pyrazole compounds, and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are useful for the treatment of mammalian infertility.

Claims (82)

1. A compound of the following Formula I;

wherein R 1 is optionally substituted alkyl or para substituted phenyl;

R 2 is pyridyl, quinoline or isoquinoline;

R 3 is hydrogen;

X is optionally substituted alkylene; optionally substituted alkenylene; optionally substituted alkynylene; optionally alicyclic, optionally substituted carbocyclic aryl;

Y is optionally substituted amino; optionally substituted methylene; carbonyl; or sulfonyl;

Z is an alkylamine substituted with a phenolic group on the alkyl chain; an amino acid selected from the group consisting of tyrosine, homo-tyrosine, β-homo-tyrosine, meta-tyrosine, threonine, serine, 4-hydroxymethyl-phenylalanine, 4-amino-phenylalanine, 4-acetyl-amino-phenylalanine, and 4-hydroxy-α-phenylglycine; m is 0 or 1; n is 0 or 1; and pharmaceutically acceptable salts thereof.

2. A compound of claim 1 wherein the compound is of the following Formula IA:

wherein R 1 is optionally substituted alkyl or para substituted phenyl;

R 2 is pyridyl, quinoline or isoquinoline;

R 3 is hydrogen;

X is optionally substituted alkylene; optionally substituted alkenylene; optionally substituted alkynylene; optionally alicyclic, optionally substituted carbocyclic aryl;

Y is optionally substituted amino; optionally substituted methylene; carbonyl; or sulfonyl;

Z is an alkylamine substituted with a phenolic group on the alkyl chain; an amino acid selected from the group consisting of tyrosine, homo-tyrosine, β-homo-tyrosine, meta-tyrosine, threonine, serine, 4-hydroxymethyl-phenylalanine, 4-amino-phenylalanine, 4-acetyl-amino-phenylalanine, and 4-hydroxy-α-phenylglycine; m is 0 or 1; n is 0 or 1; and pharmaceutically acceptable salts thereof.

3. A compound of claim 1 wherein R 1 is optionally substituted alkyl.

4. A compound of claim 1 wherein R 1 is arylalkyl.

5. A compound of claim 1 wherein R 1 is para substituted phenyl.

6. A compound of claim 1 wherein R 1 is phenyl substituted by alkyl in the 4-position.

7. A compound of claim 1 wherein R 2 is pyridyl.

8. A compound of claim 1 wherein R 2 is quinoline.

9. A compound of claim 1 wherein R 2 is isoquinoline.

10. A compound of claim 1 wherein X is an optionally substituted alkylene group.

11. A compound of claim 1 wherein X is an optionally substituted carbocyclic aryl.

12. A compound of claim 1 wherein X is —CH 2 CH 2 CH 2 CH 2 — or —CH 2 CH 2 CH 2 CH 2 CH 2 —.

13. A compound of claim 1 wherein the compound is selected from the group consisting of:

N-{5-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-5-pyridin-3-yl-1H-pyrazol-3-yl]pentanoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-pyridin-4-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-5-pyridin-4-yl-1H-pyrazol-3-yl]pentanoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl]pentanoyl}-N,N-dimethyltyrosinamide;

N-3-[1-(4-tert-butylphenyl)-5-pyridin-3-yl-1H-pyrazol-3-yl]propanoyl)tyrosinamide;

N-3-[1-(4-tert-butylphenyl)-3-pyridin-5-yl-1H-pyrazol-3-yl]propanoyl)tyrosinamide;

N-[4-(1-butyl-isoquinolin-3-yl-1H-pyrazol-5-yl)benzoyl]tyrosinamide;

N-{5-[1-(4-isopropylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{6-[1-(4-isopropylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}tyrosinamide;

N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}-3-hydroxyphenylalaninamide;

N-[5-(1-butyl-isoquinolin-3-yl-1H-pyrazol-5-yl)pentanoyl]tyrosinamide;

N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}serinamide;

N-{6-[1-(4-iso-propylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}serinamide;

N-{6-[1-(4-iso-propylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}threonamide;

N-{5-[1-(4-isopropylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]-N-[2-4-hydroxyphenyl)ethyl]hexanamide;

N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-isoquinolin-3-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{6-[1-(4-tert-butylphenyl)-3-isoquinolin-3-yl-1H-pyrazol-5-yl]hexanoyl}tyrosinamide;

N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}-N-methyltyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-isoquinolin-3-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}-4-(hydroxymethyl)phenylalaninamide;

4-amino-N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}phenylalaninamide;

4-(acetylamino)-N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}phenylalaninamide;

4-(aminocarbonyl)-N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}phenylalaninamide;

N-butyl-N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}tyrosinamide;

N-{6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanoyl}threonamide;

N-[2-amino-1-(4-hydroxyphenyl)-2-oxoethyl]-6-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]hexanamide;

N-[2-amino-1-(4-hydroxyphenyl)-2-oxoethyl]-4-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]benzamide;

4-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]-N-[2-(4-hydroxyphenyl)ethyl]benzamide;

N-{3-[1-(4-tert-butylphenyl)-3-isoquinolin-3-yl-1H-pyrazol-5-yl]benzoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-pyridin-4-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{3-[1-(4-tert-butylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl]benzoyl}tyrosinamide;

N-{3-[1-(4-tert-butylphenyl)-3-isoquinolin-3-yl-1H-pyrazol-5-yl]benzoyl}tyrosinamide;

N-{3-[1-(4-tert-butylphenyl)-3-quinolin-3-yl-1H-pyrazol-5-yl]benzoyl}tyrosinamide;

N-{3-[3-isoquinolin-3-yl-1-(4-propylphenyl)-1H-pyrazol-5-yl]benzoyl}tyrosinamide;

N-{3-[1-(4-tert-butylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl]benzoyl}tyrosinamide;

N-{4-[1-(4-tert-butylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl]benzoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-pyridin-4-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{3-[1-(4-tert-butylphenyl)-3-pyridin-4-yl-1H-pyrazol-5-yl]benzoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-pyridin-3-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-[3-(1-butyl-3-isoquinolin-3-yl-1H-pyrazol-5-yl)benzoyl]tyrosinamide;

N-{3-[1-(4-tert-butylphenyl)-3-pyridin-4-yl-1H-pyrazol-5-yl]propyl}tyrosinamide;

N-acetyl-N-{3-[1-(4-tert-butylphenyl)-3-pyridin-4-yl-1H-pyrazol-5-yl]propyl}tyrosinamide;

N-[1-(aminocarbonyl)-3-(4-hydroxyphenyl)propyl]-5-[1-(4-tert-butylphenyl)-3-pyridin-2-yl-1H-pyrazol-5-yl]pentanamide;

N-{5-[1-(4-tert-butylphenyl)-3-quinolin-3-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-[5-(1-butyl-3-quinolin-6-yl-1H-pyrazol-5-yl)pentanoyl]tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-quinolin-6-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide;

N-{5-[1-(4-tert-butylphenyl)-3-quinolin-6-yl-1H-pyrazol-5-yl]pentanoyl}tyrosinamide; or an optical isomer, racemate or tautomer of any one thereof or a pharmaceutically acceptable salt of any one thereof.

14. A compound that is:

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and one or more compounds as in claim 1 or 14 .

16. A pharmaceutical composition comprising one or more compounds as in claim 1 or 14 wherein the composition is in an oral dosage form.

17. A compound of claim 1 , wherein Z is tyrosine.

18. A compound of claim 1 , wherein Z is selected from —NHCH(CH 2 C 6 H 4 OH)C(═O)NH 2 , —NH{CH 2 C 6 H 3 —(N═C—NH—)}C(═O)NH 2 , and —NH{CH 2 C 6 H 3 —(N═N—NH—)}C(═O)NH 2 .

19. A compound of claim 1 , wherein Z is —NHCH(CH 2 C 6 H 4 OH)C(O)NH 2 .

Assignments (3)
CHANGE OF NAME Recorded Dec 3, 2009
From: LABORATOIRES SERONO SA
To: MERCK SERONO SA
Reel/Frame 023602/0182 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 11, 2007
From: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
To: LABORATOIRES SERONO SA
Reel/Frame 019966/0026 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2003
From: SHROFF, HITESH; REDDY, ADULLA P.; EL TAYAR, NABIL; BRUGGER, NADIA; JORAND-LEBRUN, CATHERINE
To: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
Reel/Frame 013850/0400 →